PPCB
Propanc Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · AU
$1.01
−0.98%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-31.2%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 23, 2023 | ZELINGER JOSEF · director | A-Award | 15,000,000 | $0.01 |
| Aug 20, 2021 | Kenyon Julian Norman · director, officer: Chief Scientific Officer | A-Award | 3,420,000 | $0.00 |
| Aug 20, 2021 | Nathanielsz James Andrew · director, officer: CEO/CFO | A-Award | 5,928,000 | $0.00 |
| Aug 20, 2021 | Nathanielsz James Andrew · director, officer: CEO/CFO | A-Award | 2,800,000 | $0.00 |
| May 22, 2019 | Kenyon Julian Norman · director, officer: Chief Scientific Officer | A-Award | 9,750,000 | $0.01 |
| May 17, 2019 | Nathanielsz James Andrew · director, officer: CEO, Acting CFO, Chairman | A-Award | 19,500,000 | $0.01 |
| Sep 27, 2016 | Nathanielsz James Andrew · director, officer: CEO, CFO, Secretary, Treasurer | A-Award | 71,500,000 | $0.03 |
| Sep 27, 2016 | Kenyon Julian Norman · director | A-Award | 71,500,000 | $0.03 |
| Jan 13, 2015 | Nathanielsz James Andrew · director, 10 percent owner, officer: Chief Executive Officer | Sale | 250,000 | $0.20 |
| Jan 13, 2015 | Nathanielsz James Andrew · director, 10 percent owner, officer: Chief Executive Officer | Sale | 5,000 | $0.20 |
| Jan 13, 2015 | Nathanielsz James Andrew · director, 10 percent owner, officer: Chief Executive Officer | Sale | 5,500 | $0.20 |
| Jan 13, 2015 | Nathanielsz James Andrew · director, 10 percent owner, officer: Chief Executive Officer | Sale | 15,000 | $0.20 |
| Jan 13, 2015 | Nathanielsz James Andrew · director, 10 percent owner, officer: Chief Executive Officer | Sale | 55,000 | $0.09 |
| Jan 13, 2015 | Nathanielsz James Andrew · director, 10 percent owner, officer: Chief Executive Officer | A-Award | 500,000 | $0.00 |
| Aug 24, 2012 | Nathanielsz James Andrew · director, 10 percent owner, officer: Chief Executive Officer | Purchase | 250,000 | $0.20 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 23, 2023